Results 81 to 90 of about 1,097,021 (302)

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

open access: yesMolecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic   +15 more
wiley   +1 more source

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

open access: yes, 2020
Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis.
Samer Saadi   +7 more
core   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach   +9 more
wiley   +1 more source

Immune Checkpoint Inhibitors in NSCLC [PDF]

open access: yesCurrent Treatment Options in Oncology, 2014
Lung cancer is the leading cause of cancer-related mortality worldwide. Cytotoxic chemotherapy and tyrosine kinase inhibitors provide palliation and prolong survival, however, the median survival for patients with metastatic disease remains poor and more effective therapies are needed.
Douglas B, Johnson   +2 more
openaire   +2 more sources

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

open access: yesMolecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang   +9 more
wiley   +1 more source

Commentary: The checkpoint before checkpoint inhibitors [PDF]

open access: yesThe Journal of Thoracic and Cardiovascular Surgery, 2020
William A, Blessing, Yolonda L, Colson
openaire   +2 more sources

Supplementary Table S1: Combination therapies in clinical trials involving immune checkpoint inhibitors from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

open access: yes, 2018
Supplementary Table S1 summarizes clinical trials of combinatorial therapies that include immune checkpoint inhibitors. This includes combined immune checkpoint blockade, as well as the combination of immune checkpoint inhibitors with radiotherapy, and ...
Richard A. Scolyer (8553126)   +3 more
core   +1 more source

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

open access: yesImmunoTargets and Therapy, 2022
Adam Yuh Lin,1 Joseph Michael Schnitter,2 Leo I Gordon1 1Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Department of Medicine, Feinberg School of Medicine, Northwestern ...
Lin AY, Schnitter JM, Gordon LI
doaj  

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

open access: yesMolecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim   +7 more
wiley   +1 more source

Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer

open access: yes, 2016
Advanced non-small-cell lung cancer (NSCLC) has a poor prognosis with few treatment options available for patients after failure of first-line therapy.
O'Byrne, Kenneth J., Decatris, Marios P.
core   +1 more source

Home - About - Disclaimer - Privacy